Cardiovasc Diabetol:2型糖尿病中氧化应激、炎症反应、内皮功能的紊乱和影响

2016-05-18 李月 译 MedSci原创

    氧化应激、炎症反应和内皮功能的紊乱与心血管疾病发病互为相关因素,但是它们与2型糖尿病的联系目前尚未明确。研究人员通过检测2型糖尿病相关生化标志物探讨这一联系。    研究选取了中青年人冠状动脉危险因素研究(CARDIA)中的2339名对象,研究对象的平均年龄为40.1±3.6岁,包括44%黑人和58%女性,所有研究对象均未患糖尿病,且接受了长达10年

氧化应激、炎症反应和内皮功能的紊乱与心血管疾病发病互为相关因素,但是它们与2型糖尿病的联系目前尚未明确。研究人员通过检测2型糖尿病相关生化标志物探讨这一联系。

研究选取了中青年人冠状动脉危险因素研究(CARDIA)中的2339名对象,研究对象的平均年龄为40.1±3.6岁,包括44%黑人和58%女性,所有研究对象均未患糖尿病,且接受了长达10年的随访。统计采用Cox回归评估2型糖尿病发生的危险比(校正其他生化标志物、人口结构和生活方式、饮食习惯、BMI、代谢综合征等因素后)。
 
结果显示F2-iPs(F2-iPs是细胞膜脂质中花生四烯酸经自由基诱导产生的过氧化产物,为体内氧化应激和过氧化的标志物)和氧化型LDL与2型糖尿病的发生均呈正相关,但该相关性经过校正BMI后有所减弱。C反应蛋白与2型糖尿病的发生在校正上述因素后呈正相关,四分位数与一分位数(Q4 vs Q1)之间的危险比HR(95%CI)=2.21 (1.26–3.88)。校正所有因素后,2型糖尿病发生的危险比(95%CI)在反映内皮功能紊乱的生化标志物细胞粘附分子-1(ICAM-1)和内皮细胞选择素(E-selectin)中分别为1.64 (0.96–2.81)和 1.68 (1.04–2.71)(Q4 vs Q1)。这两种生化标志物的危险评分联合BMI、临床检测等将2型糖尿病发病的预测概率提高了9%:替代风险评分概率的高四分位和低四分位(75 vs 25th %)的相对危险度RR=1.09(1.06-1.13),P<0.0001。

因此,炎症反应和内皮功能紊乱的生化标志物与2型糖尿病的发生呈正相关,ICAM-1和E-selectin有助于预测2型糖尿病的发生。

原始出处:

Odegaard AO,Jacobs DR Jr,Sanchez OA, Goff DC Jr, Reiner AP,Gross MD.Oxidative Stress, Inflammation, Endothelial Dysfunction and Incidence of Type 2 Diabetes.Cardiovasc Diabetol. 2016;15(51) 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759666, encodeId=4d561e5966620, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jun 21 10:51:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637330, encodeId=346e163e33078, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 08 03:51:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938546, encodeId=3ff319385462e, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Apr 15 18:51:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320819, encodeId=e5d4132081994, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445125, encodeId=2fb51445125ce, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450018, encodeId=97621450018ef, content=<a href='/topic/show?id=85eb304409c' target=_blank style='color:#2F92EE;'>#内皮功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30440, encryptionId=85eb304409c, topicName=内皮功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41d5536295, createdName=zhangxingru, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759666, encodeId=4d561e5966620, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jun 21 10:51:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637330, encodeId=346e163e33078, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 08 03:51:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938546, encodeId=3ff319385462e, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Apr 15 18:51:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320819, encodeId=e5d4132081994, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445125, encodeId=2fb51445125ce, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450018, encodeId=97621450018ef, content=<a href='/topic/show?id=85eb304409c' target=_blank style='color:#2F92EE;'>#内皮功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30440, encryptionId=85eb304409c, topicName=内皮功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41d5536295, createdName=zhangxingru, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759666, encodeId=4d561e5966620, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jun 21 10:51:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637330, encodeId=346e163e33078, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 08 03:51:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938546, encodeId=3ff319385462e, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Apr 15 18:51:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320819, encodeId=e5d4132081994, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445125, encodeId=2fb51445125ce, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450018, encodeId=97621450018ef, content=<a href='/topic/show?id=85eb304409c' target=_blank style='color:#2F92EE;'>#内皮功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30440, encryptionId=85eb304409c, topicName=内皮功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41d5536295, createdName=zhangxingru, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
    2017-04-15 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=1759666, encodeId=4d561e5966620, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jun 21 10:51:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637330, encodeId=346e163e33078, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 08 03:51:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938546, encodeId=3ff319385462e, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Apr 15 18:51:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320819, encodeId=e5d4132081994, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445125, encodeId=2fb51445125ce, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450018, encodeId=97621450018ef, content=<a href='/topic/show?id=85eb304409c' target=_blank style='color:#2F92EE;'>#内皮功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30440, encryptionId=85eb304409c, topicName=内皮功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41d5536295, createdName=zhangxingru, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1759666, encodeId=4d561e5966620, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jun 21 10:51:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637330, encodeId=346e163e33078, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 08 03:51:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938546, encodeId=3ff319385462e, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Apr 15 18:51:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320819, encodeId=e5d4132081994, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445125, encodeId=2fb51445125ce, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450018, encodeId=97621450018ef, content=<a href='/topic/show?id=85eb304409c' target=_blank style='color:#2F92EE;'>#内皮功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30440, encryptionId=85eb304409c, topicName=内皮功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41d5536295, createdName=zhangxingru, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1759666, encodeId=4d561e5966620, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jun 21 10:51:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637330, encodeId=346e163e33078, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Apr 08 03:51:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938546, encodeId=3ff319385462e, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Apr 15 18:51:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320819, encodeId=e5d4132081994, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445125, encodeId=2fb51445125ce, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450018, encodeId=97621450018ef, content=<a href='/topic/show?id=85eb304409c' target=_blank style='color:#2F92EE;'>#内皮功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30440, encryptionId=85eb304409c, topicName=内皮功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41d5536295, createdName=zhangxingru, createdTime=Fri May 20 07:51:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]

相关资讯

J Neurosurg Sci:碧萝芷可增强婴儿潮这代人的的认知功能

碧萝芷是法国沿海松树皮的提取物,可提高身体健康但是氧化应激水平较高人群的认知功能。该研究结果在线发表于Journal of Neurosurgical Sciences。

J Intern Med:减重手术的潜在性益处的原因是什么?

对于病态肥胖,目前通过手术是减少体重的最有效方式,也是治疗该疾病的最有效的方式。目前有现象表明减重手术对于心血管疾病有潜在的益处,但是具体机制是什么,为什么会这样,却依旧含糊不明确,不过相关研究发现了提示炎症抑制的标志物。研究者假设对于减重手术带来的对患者相关的潜在益处,抗炎、抗氧化应激反应功不可没,并且这些也是有相关临床试验证实过的。为了验证假设,研究者进行了一项研究,对20名研究对象,在术前和

Medicine:肥胖诱导的氧化应激与机体牙周疾病的发生有关

Medicine:肥胖诱导的氧化应激与机体牙周疾病的发生有关牙周病是一种慢性炎症性疾病,更常见于肥胖人群。局部和全身的氧化应激可能是牙周病和肥胖早期关联的因素。本研究旨在检测肥胖者的牙周疾病易感性的增加是否与局部和全身的氧化应激有关。因此,本研究中,研究人员对比了年轻肥胖女性与年龄匹配的较瘦女性的牙周状况及全身(血清)和局部(龈沟液)氧化应激标志物的状态。研究共纳入了20名肥胖女性和20名较瘦的女

J Physiol:年龄的增加可减轻血管氧化应激损伤

氧化应激与许多疾病的发生都有关,包括高血压、糖尿病、部分癌症、心脏病、老年痴呆和年龄相关性疾病。活性氧(ROS)的产生和抗氧化剂的清除之间的不平衡导致氧化应激的产生,且氧化应激通过攻击细胞DNA、蛋白质和脂类物质,进而造成细胞的损伤。发表在The Journal of Physiology的一篇杂志描述了密苏里堪萨斯大学医学院的研究人员对小鼠的实验,该实验表明衰老(年龄增加)对氧化应激有明显的保护

Nature:黑色素瘤细胞能有效抵御活性氧化应激压力

图片来自:www.malignant-melanoma.org 活性氧和抗氧化分子在促进或抑制肿瘤发展中扮演的角色一直存在争议。在这个问题上,美国德州西南医学中心的科学家们认为,黑色素瘤细胞如果能够细胞压力,即能够解决活性氧化物的问题,那么这些细胞就能高效地在血液循环系统中移动,并导致癌症的扩散。作者们还表明,抑制这些小鼠中处理活性氧化物的代谢途径,可以有效地减弱了黑色素瘤细胞的转移。 活

Electromagn Biol Med:适当远离手机——手机辐射确可致癌!

最新的一项研究表明,无线设备发出的辐射引起机体代谢紊乱可能与机体的某些疾病相关,如各种神经退行性疾病和癌症。“低强度射频辐射生物活性的氧化机制,”最新发表于Electromagnetic Biology & Medicine上的一篇综述探讨了关于低强度射频辐射对活细胞代谢影响的数据。共同作者 Dr. Igor Yakymenko将这种失衡称为氧化应激,定义为“活性氧(ROS)产量与抗氧化防